Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00964730 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm
A Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 1
- Development phase
- 135
- Enrollment target
NCT00964730: Completed Phase 1 study, sponsored by Teva Branded Pharmaceutical Products R&D.
NCT00964730 is a Phase 1 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 135 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (125% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00964730, a Phase 1 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 135 participants
- Enrollment target
Study Summary
The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
Interventions
- DRUG Placebo
- DRUG Moxifloxacin
- DRUG Talampanel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 135 participants |
| Start Date | 2009-10 |
| Est. Completion | 2010-02 |
| Phase | Phase 1 |
What the finished NCT00964730 record still lists
NCT00964730 is an interventional study that assigns participants to a tested intervention. The registered 135 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (125% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00964730 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00964730 about?
NCT00964730 is a clinical study titled "A Phase 1 Study to Investigate the Effects of Talampanel on the Heart Rhythm". The purpose of this study is to assess whether multiple doses of Talampanel increase the QT interval when compared to placebo
What is the current status of trial NCT00964730?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 135 participants. The study started on 2009-10. Estimated completion is 2010-02.
What interventions are being tested in trial NCT00964730?
The interventions under investigation include: Placebo (DRUG), Moxifloxacin (DRUG), Talampanel (DRUG).
Who is sponsoring clinical trial NCT00964730?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00964730's enrollment target sits among peer trials
135 425th of 2000 higher than 1,574 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00870129 · 135 participants · NA
Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors
- NCT03666000 · 135 participants · Phase 1
Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)
- NCT04891510 · 135 participants · NA
A Comparative Analysis of REVOLVE, LipoGrafter, and Viality in Autologous Fat Grafting During Breast Surgery
- NCT05121051 · 135 participants · Phase 2
Testing the Effect of the Broccoli Seed and Sprout Extract, Avmacol ES, on the Cancer Causing Substances of Tobacco in Heavy Smokers
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia